Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.


Journal

Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672

Informations de publication

Date de publication:
09 2023
Historique:
revised: 31 05 2023
received: 13 03 2023
accepted: 02 06 2023
pmc-release: 01 09 2024
medline: 18 8 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

Among persons with HIV (PWH), higher alcohol use and having hepatitis C virus (HCV) are separately associated with increased morbidity and mortality. We investigated whether the association between alcohol use and mortality among PWH is modified by HCV. Data were combined from European and North American cohorts of adult PWH who started antiretroviral therapy (ART). Self-reported alcohol use data, collected in diverse ways between cohorts, were converted to grams/day. Eligible PWH started ART during 2001-2017 and were followed from ART initiation for mortality. Interactions between the associations of baseline alcohol use (0, 0.1-20.0, >20.0 g/day) and HCV status were assessed using multivariable Cox models. Of 58,769 PWH, 29,711 (51%), 23,974 (41%) and 5084 (9%) self-reported alcohol use of 0 g/day, 0.1-20.0 g/day, and > 20.0 g/day, respectively, and 4799 (8%) had HCV at baseline. There were 844 deaths in 37,729 person-years and 2755 deaths in 443,121 person-years among those with and without HCV, respectively. Among PWH without HCV, adjusted hazard ratios (aHRs) for mortality were 1.18 (95% CI: 1.08-1.29) for 0.0 g/day and 1.84 (1.62-2.09) for >20.0 g/day compared with 0.1-20.0 g/day. This J-shaped pattern was absent among those with HCV: aHRs were 1.00 (0.86-1.17) for 0.0 g/day and 1.64 (1.33-2.02) for >20.0 g/day compared with 0.1-20.0 g/day (interaction p < .001). Among PWH without HCV, mortality was higher in both non-drinkers and heavy drinkers compared with moderate alcohol drinkers. Among those with HCV, mortality was higher in heavy drinkers but not non-drinkers, potentially due to differing reasons for not drinking (e.g. illness) between those with and without HCV.

Identifiants

pubmed: 37338017
doi: 10.1111/jvh.13863
pmc: PMC10526649
mid: NIHMS1906634
doi:

Banques de données

ClinicalTrials.gov
['NCT02149004']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

775-786

Subventions

Organisme : NIAAA NIH HHS
ID : U01 AA026230
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA020794
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI067039
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA026224
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI110527
Pays : United States
Organisme : Wellcome Trust
ID : 222770/Z/21/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAAA NIH HHS
ID : U01 AA026209
Pays : United States

Informations de copyright

© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.

Références

HIV Med. 2014 Apr;15(4):203-12
pubmed: 24245909
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):302-9
pubmed: 26444500
Clin Infect Dis. 2014 May;58(10):1449-58
pubmed: 24569533
HIV Med. 2017 May;18(5):332-341
pubmed: 27679418
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):348-54
pubmed: 25848927
Curr Opin HIV AIDS. 2016 Sep;11(5):507-513
pubmed: 27254749
J Gen Intern Med. 2007 Jun;22(6):822-5
pubmed: 17503108
Clin Infect Dis. 2014 Jul 15;59(2):287-97
pubmed: 24771333
Hepatology. 2018 Jul;68(1):32-47
pubmed: 29377274
Clin Gastroenterol Hepatol. 2005 Nov;3(11):1150-9
pubmed: 16271348
AIDS. 2014 May 15;28(8):1181-91
pubmed: 24901259
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
Lancet HIV. 2015 Aug;2(8):e319-27
pubmed: 26423374
J Clin Med. 2021 Jan 14;10(2):
pubmed: 33466907
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):135-143
pubmed: 29112041
Drug Alcohol Depend. 2016 Apr 1;161:95-103
pubmed: 26861883
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Lancet Infect Dis. 2015 Jul;15(7):810-8
pubmed: 26070969
N Engl J Med. 2015 Aug 20;373(8):705-13
pubmed: 26196665
J Am Coll Cardiol. 2017 Jan 3;69(1):13-24
pubmed: 28057245
AIDS. 2014 Aug 24;28(13):1957-65
pubmed: 25259703
Aliment Pharmacol Ther. 2003 Apr;17(8):1031-7
pubmed: 12694085
Int J Epidemiol. 2014 Jun;43(3):691-702
pubmed: 23599235
J Hepatol. 2015 Sep;63(3):573-80
pubmed: 25937433
Alcohol Alcohol. 2013 Sep-Oct;48(5):564-9
pubmed: 23690232
Clin Infect Dis. 2009 Jul 15;49(2):225-32
pubmed: 19508169
AIDS Behav. 2016 Mar;20(3):548-54
pubmed: 26080690
AIDS. 2015 Jun 19;29(10):1205-15
pubmed: 25870984
Clin Infect Dis. 2001 Aug 15;33(4):562-9
pubmed: 11462196
Clin Infect Dis. 2016 Sep 15;63(6):821-829
pubmed: 27307505
J Viral Hepat. 2009 Sep;16(9):644-9
pubmed: 19243494
J Viral Hepat. 2023 Sep;30(9):775-786
pubmed: 37338017
J Viral Hepat. 2016 Jan;23(1):47-52
pubmed: 26390144
Alcohol Alcohol. 2021 Jan 4;56(1):8-16
pubmed: 32869059

Auteurs

Adam Trickey (A)

Population Health Sciences, University of Bristol, Bristol, UK.

Suzanne M Ingle (SM)

Population Health Sciences, University of Bristol, Bristol, UK.

Anders Boyd (A)

Stichting HIV Monitoring, Amsterdam, The Netherlands.
Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Amsterdam UMC, University of Amsterdam, Infectious Diseases, Amsterdam, The Netherlands.

M John Gill (MJ)

South Alberta HIV Clinic, Department of Medicine, University of Calgary, Calgary, Canada.

Sophie Grabar (S)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Department of Public Health, AP-HP, St Antoine Hospital, Paris, France.

Inma Jarrin (I)

National Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain.
CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III.

Niels Obel (N)

Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Giota Touloumi (G)

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Robert Zangerle (R)

Austrian HIV Cohort Study (AHIVCOS), Medizinische Universität Innsbruck, Innsbruch, Austria.

Andri Rauch (A)

Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Christopher T Rentsch (CT)

Yale School of Medicine and VA Connecticut Healthcare System, West Haven, Connecticut, USA.
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.

Derek D Satre (DD)

Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, USA.
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.

Michael J Silverberg (MJ)

Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.

Fabrice Bonnet (F)

Institut Bergonié, BPH, U1219, CIC-EC 1401, INSERM, Univ. Bordeaux, Bordeaux, France.
CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, INSERM, Institut Bergonié Hôpital St-André, CIC-EC 1401, Bordeaux, France.

Jodie Guest (J)

Atlanta VA Medical Center, Decatur, Georgia, USA.
Rollins School of Public Health at Emory University, Atlanta, Georgia, USA.

Greer Burkholder (G)

University of Alabama, Birmingham, Alabama, USA.

Heidi Crane (H)

Department of Medicine, University of Washington, Seattle, Washington, USA.

Ramon Teira (R)

Servicio de Medicina Interna, Hospital Universitario de Sierrallana, Torrelavega, Spain.

Juan Berenguer (J)

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Christoph Wyen (C)

Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.

Sophie Abgrall (S)

APHP, Service de Médecine Interne, Hôpital Béclère, Clamart, France.
CESP, INSERM U1018, Université Paris-Saclay, UVSQ, Le Kremlin-Bicêtre, Villejuif, France.

Mojgan Hessamfar (M)

Institut Bergonié, BPH, U1219, CIC-EC 1401, INSERM, Univ. Bordeaux, Bordeaux, France.
CHU de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, INSERM, Institut Bergonié Hôpital St-André, CIC-EC 1401, Bordeaux, France.

Peter Reiss (P)

Stichting HIV Monitoring, Amsterdam, The Netherlands.
Department of Global Health, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.

Antonella d'Arminio Monforte (A)

Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University Hospital, Milan, Italy.

Kathleen A McGinnis (KA)

Yale School of Medicine and VA Connecticut Healthcare System, West Haven, Connecticut, USA.

Jonathan A C Sterne (JAC)

Population Health Sciences, University of Bristol, Bristol, UK.
NIHR Bristol Biomedical Research Centre, Bristol, UK.
Health Data Research UK South-West, Bristol, UK.

Linda Wittkop (L)

Institut Bergonié, BPH, U1219, CIC-EC 1401, INSERM, Univ. Bordeaux, Bordeaux, France.
INRIA SISTM Team, Talence, France.
CHU de Bordeaux, Service d'information Médicale, INSERM, Institut Bergonié, CIC-EC 1401, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH